Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial
Key Points
To explore the effectiveness of subcutaneous infliximab for personalized therapy in managing symptoms of Crohn's disease.
Conducted a phase 3 randomised, placebo-controlled trial.
Used subcutaneous infliximab as the intervention.
Monitored symptom responses and dynamics.
Participants receiving infliximab showed significant symptom improvements compared to placebo.
Results suggest a potential for personalized treatment strategies in Crohn's disease.
Abstract
ClinicalTrials. gov identifier, NCT03945019 (08 May 2019).
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial | Synapse